Healthcare Equipment and Supplies
Company Overview of Celleration, Inc.
Celleration, Inc., a medical device company, develops and commercializes therapeutic ultrasound healing technologies in the United States. It offers MIST Therapy, a painless, noncontact, and low frequency ultrasound delivered through a saline mist to the wound bed. The company serves patients, medical professionals, and payers. Celleration, Inc. was formerly known as Advanced Medical Applications, Inc. The company was founded in 1999 and is based in Eden Prairie, Minnesota. As of May 29, 2015, Celleration, Inc. operates as a subsidiary of Alliqua BioMedical, Inc.
6321 Bury Drive
Eden Prairie, MN 55346
Founded in 1999
Key Executives for Celleration, Inc.
Chief Executive Officer, President and Director
Vice President of Medical Affairs
Vice President of Research & Development
Area Director of Sales - Western US
Area Director of Sales - Eastern US
Compensation as of Fiscal Year 2015.
Celleration, Inc. Key Developments
Alliqua, Inc., Celleration Inc. - M&A Call
Feb 2 15
To discuss the acquisition of Celleration, Inc.
Celleration, Inc. Announces Statistically Significant Better Healing with MIST® Therapy in the IN-BALANCE VLU Randomized Control Trial
Jan 27 15
Celleration Inc. announced the publication of results from the IN-BALANCE VLU prospective, randomized controlled trial in the January edition of Ostomy & Wound Management. IN-BALANCE was conducted in 22 US outpatient healthcare facilities comparing the percent wound area reduction after 4 weeks of treatment with guideline-driven standard care (SC) plus MIST Ultrasound Healing Therapy (MIST + SC) to SC alone in nonresponding lower extremity venous leg ulcers (VLU). Of the 112 eligible participants, 81 were identified as non-responding during the two week run-in period and were randomized. The average wound size reduction at 4 weeks was 61.6% in the MIST+SC compared to 45% in the SC alone group (P = 0.02). The statistical significance was unchanged when adjusting for wound size and age. In addition, MIST Therapy showed a statistically significant reduction in pain (P = 0.01) during the same period.
Celleration Inc. Announces FDA Clearance for Next Generation UltraMIST System
Aug 20 14
Celleration Inc. announced that they received FDA clearance for their next generation UltraMIST(TM) System. The UltraMIST System is Celleration's latest addition to its line of MIST(R) Therapy products. MIST Therapy is low-frequency ultrasound delivered through a saline mist to accelerate wound healing. Unlike conventional wound treatments that are limited to treating the surface, MIST Therapy delivers ultrasound energy into and below the wound bed to stimulate cells and shorten the healing process.
Similar Private Companies By Industry
Recent Private Companies Transactions
February 2, 2015
Most Searched Private Companies
Sponsored Financial Commentaries